Correlation of immune reconstitution and clinical outcomes after haplo-HCT. (A) Probability of CMV reactivation after haplo-HCT and MD-HCT. (B) Comparison of CD16⁻/CD16⁺ NK-cell ratio in patients after haplo-HCT with and without CMV reactivation after transplant. The median values per microliter are represented at each time point (**P < .01; *P < .05). (C) Probability of cGVHD after haplo-HCT and MD-HCT. (D) Comparison of CD16⁻/CD16⁺ NK-cell ratio in patients after haplo-HCT with and without cGVHD after transplant; the median values per microliter are represented at each time point. (E) Distribution of PD-1⁺ CM and EM CD4⁺ Treg cells at 1 month after haplo-HCT according to cGVHD onset. Values are expressed as median and range. Statistically significant differences are noted (**P < .01; *P < .05; Wilcoxon rank-sum test). CM T cells are defined as CD45RO⁺CD62L and EM as CD45RO⁺CD62L⁻ T lymphocytes. See supplemental Tables 10 and 11 for the median absolute values along with the corresponding interquartile values and P values for panels B and D.